{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=37", "query": { "intervention": "Dose level 3", "page": 37 }, "page_size": 10 }, "pagination": { "page": 37, "page_size": 10, "total_count": 17830, "total_pages": 1783, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=38&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=36&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T07:30:08.244Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01153191", "title": "Effectiveness for Interventions to Minimize Surgical Site Infections", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infections" ], "interventions": [ { "name": "Normal saline pressurized irrigation", "type": "PROCEDURE" }, { "name": "sub-q gentamicin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Dallas VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 120, "start_date": "2010-08", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2011-11-04", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01153191" }, { "nct_id": "NCT05904691", "title": "Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neovascular Age-related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "OCU-10-C-110 for Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocugenix Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 24, "start_date": "2023-11-01", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 3, "location_summary": "Carmel, Indiana • Abilene, Texas • Willow Park, Texas", "locations": [ { "city": "Carmel", "state": "Indiana" }, { "city": "Abilene", "state": "Texas" }, { "city": "Willow Park", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05904691" }, { "nct_id": "NCT05823974", "title": "A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "F2C22C/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2B22A/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2B22B/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2B22C/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2B22D/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2B22E/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2F22A/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2F22B/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2F22C/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2F22D/DL001Z", "type": "BIOLOGICAL" }, { "name": "F2F22E/DL001Z", "type": "BIOLOGICAL" }, { "name": "Control 1", "type": "COMBINATION_PRODUCT" }, { "name": "F2F23D/DL001Z-NH", "type": "BIOLOGICAL" }, { "name": "F2F23A/DL001Z-NH", "type": "BIOLOGICAL" }, { "name": "F2F23B/DL001Z-NH", "type": "BIOLOGICAL" }, { "name": "Control 2", "type": "COMBINATION_PRODUCT" }, { "name": "F2F23C/DL001Z-NH", "type": "BIOLOGICAL" }, { "name": "Control 3", "type": "COMBINATION_PRODUCT" }, { "name": "F2F22F/DL001Z", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 1275, "start_date": "2023-04-27", "completion_date": "2024-12-18", "has_results": true, "last_update_posted_date": "2025-07-23", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 24, "location_summary": "Hialeah, Florida • Miami, Florida • Chicago, Illinois + 21 more", "locations": [ { "city": "Hialeah", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Valparaiso", "state": "Indiana" }, { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05823974" }, { "nct_id": "NCT06805825", "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumors", "Small-cell Lung Cancer", "Adenoid Cystic Carcinoma", "Uveal Melanoma", "Neuroendocrine Tumors", "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "NN3201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novelty Nobility, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-02-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 5, "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805825" }, { "nct_id": "NCT02631876", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epithelial Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "Mirvetuximab soravtansine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 366, "start_date": "2016-03-02", "completion_date": "2020-01", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631876" }, { "nct_id": "NCT00970489", "title": "Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Omega -3 fatty acids", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1516, "start_date": "2010-08", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2017-04-10", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00970489" }, { "nct_id": "NCT00042874", "title": "Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2002-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042874" }, { "nct_id": "NCT07707674", "title": "Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "XNW28012", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Evopoint Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-07-30", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 8, "location_summary": "Detroit, Michigan • Grand Rapids, Michigan • Lake Success, New York + 5 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07707674" }, { "nct_id": "NCT02537002", "title": "Single Dose Study of PF-05230907 in Healthy Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-05230907", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 17, "start_date": "2015-09", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-04-29", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02537002" }, { "nct_id": "NCT00266253", "title": "A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus Type 2" ], "interventions": [ { "name": "GK Activator (2)", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 220, "start_date": "2005-11", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-15T07:30:08.244Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00266253" } ] }